Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 151 of 151 entries
Sorted by: Best Match Show Resources per page
Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study.

Contemporary clinical trials communications

Kuba S, Moriuchi H, Yamanouchi K, Shibata K, Yano H, Oikawa M, Maeda S, Meng X, Morita M, Hatachi T, Otsubo R, Matsumoto M, Miyamoto J, Kanetaka K, Taniguchi H, Nagayasu T, Eguchi S.
PMID: 33718655
Contemp Clin Trials Commun. 2021 Feb 11;21:100739. doi: 10.1016/j.conctc.2021.100739. eCollection 2021 Mar.

Survival of patients with breast cancer can be prolonged by treatment with drugs, particularly new molecular-targeted drugs. However, these agents can be expensive and such treatments can be "an economic burden." In this ongoing trial, we aim to assess...

Cite
Kuba S, Moriuchi H, Yamanouchi K, et al. Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study. Contemp Clin Trials Commun. 2021;21:100739doi: 10.1016/j.conctc.2021.100739.
Kuba, S., Moriuchi, H., Yamanouchi, K., Shibata, K., Yano, H., Oikawa, M., Maeda, S., Meng, X., Morita, M., Hatachi, T., Otsubo, R., Matsumoto, M., Miyamoto, J., Kanetaka, K., Taniguchi, H., Nagayasu, T., & Eguchi, S. (2021). Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study. Contemporary clinical trials communications, 21100739. https://doi.org/10.1016/j.conctc.2021.100739
Kuba, Sayaka, et al. "Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study." Contemporary clinical trials communications vol. 21 (2021): 100739. doi: https://doi.org/10.1016/j.conctc.2021.100739
Kuba S, Moriuchi H, Yamanouchi K, Shibata K, Yano H, Oikawa M, Maeda S, Meng X, Morita M, Hatachi T, Otsubo R, Matsumoto M, Miyamoto J, Kanetaka K, Taniguchi H, Nagayasu T, Eguchi S. Protocol for studying the efficiency of ChemoCalc software in helping patients to understand drug treatment costs for breast cancer: A multicenter, open-label, randomized phase 2 study. Contemp Clin Trials Commun. 2021 Feb 11;21:100739. doi: 10.1016/j.conctc.2021.100739. eCollection 2021 Mar. PMID: 33718655; PMCID: PMC7921475.
Copy Download .nbib Format: NLM
Cross-dominant surgery using the da Vinci (Xi) surgical system in advanced rectal cancer surgery.

Techniques in coloproctology

Nonaka T, Tominaga T, Akazawa Y, Sawai T, Nagayasu T.
PMID: 34406534
Tech Coloproctol. 2022 Jan;26(1):77-78. doi: 10.1007/s10151-021-02503-x. Epub 2021 Aug 18.

No abstract available.

Cite
Nonaka T, Tominaga T, Akazawa Y, et al. Cross-dominant surgery using the da Vinci (Xi) surgical system in advanced rectal cancer surgery. Tech Coloproctol. 2021;26(1):77-78doi: 10.1007/s10151-021-02503-x.
Nonaka, T., Tominaga, T., Akazawa, Y., Sawai, T., & Nagayasu, T. (2022). Cross-dominant surgery using the da Vinci (Xi) surgical system in advanced rectal cancer surgery. Techniques in coloproctology, 26(1), 77-78. https://doi.org/10.1007/s10151-021-02503-x
Nonaka, T, et al. "Cross-dominant surgery using the da Vinci (Xi) surgical system in advanced rectal cancer surgery." Techniques in coloproctology vol. 26,1 (2022): 77-78. doi: https://doi.org/10.1007/s10151-021-02503-x
Nonaka T, Tominaga T, Akazawa Y, Sawai T, Nagayasu T. Cross-dominant surgery using the da Vinci (Xi) surgical system in advanced rectal cancer surgery. Tech Coloproctol. 2022 Jan;26(1):77-78. doi: 10.1007/s10151-021-02503-x. Epub 2021 Aug 18. PMID: 34406534.
Copy Download .nbib Format: NLM
Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial.

Journal of thoracic disease

Doi R, Miyazaki T, Tsuchiya T, Matsumoto K, Tomoshige K, Machino R, Mizoguchi S, Matsumoto T, Yamaguchi K, Takatsuna H, Shiosakai K, Nagayasu T.
PMID: 34795952
J Thorac Dis. 2021 Oct;13(10):6062-6070. doi: 10.21037/jtd-21-741.

BACKGROUND: Intercostal nerve damage due to thoracotomy or thoracoscopic manipulation is a major contributor to chronic postsurgical pain after pulmonary resection. Chronic postsurgical pain may last for months or years and can negatively impair physical functioning and daily activities....

Cite
Doi R, Miyazaki T, Tsuchiya T, et al. Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial. J Thorac Dis. 2021;13(10):6062-6070doi: 10.21037/jtd-21-741.
Doi, R., Miyazaki, T., Tsuchiya, T., Matsumoto, K., Tomoshige, K., Machino, R., Mizoguchi, S., Matsumoto, T., Yamaguchi, K., Takatsuna, H., Shiosakai, K., & Nagayasu, T. (2021). Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial. Journal of thoracic disease, 13(10), 6062-6070. https://doi.org/10.21037/jtd-21-741
Doi, Ryoichiro, et al. "Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial." Journal of thoracic disease vol. 13,10 (2021): 6062-6070. doi: https://doi.org/10.21037/jtd-21-741
Doi R, Miyazaki T, Tsuchiya T, Matsumoto K, Tomoshige K, Machino R, Mizoguchi S, Matsumoto T, Yamaguchi K, Takatsuna H, Shiosakai K, Nagayasu T. Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial. J Thorac Dis. 2021 Oct;13(10):6062-6070. doi: 10.21037/jtd-21-741. PMID: 34795952; PMCID: PMC8575802.
Copy Download .nbib Format: NLM
Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks.

Neuroscience letters

Kewan A, Shimatani T, Saneyasu T, Kamisoyama H, Honda K.
PMID: 34838926
Neurosci Lett. 2021 Nov 25;768:136362. doi: 10.1016/j.neulet.2021.136362. Epub 2021 Nov 25.

Glucagon-like peptide (GLP)-1 and GLP-2, proglucagon-derived brain-gut peptides, function as anorexigenic neuropeptides in mammals. We previously showed that central administration of GLP-1 and GLP-2 potently suppressed food intake in chicks. GLP-1 and GLP-2 specifically activate their receptors GLP-1 receptor...

Cite
Kewan A, Shimatani T, Saneyasu T, et al. Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks. Neurosci Lett. 2021;768:136362doi: 10.1016/j.neulet.2021.136362.
Kewan, A., Shimatani, T., Saneyasu, T., Kamisoyama, H., & Honda, K. (2021). Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks. Neuroscience letters, 768136362. https://doi.org/10.1016/j.neulet.2021.136362
Kewan, Ahmed, et al. "Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks." Neuroscience letters vol. 768 (2021): 136362. doi: https://doi.org/10.1016/j.neulet.2021.136362
Kewan A, Shimatani T, Saneyasu T, Kamisoyama H, Honda K. Comparison of the effects of intracerebroventricular administration of glucagon-like peptides 1 and 2 on hypothalamic appetite regulating factors and sleep-like behavior in chicks. Neurosci Lett. 2021 Nov 25;768:136362. doi: 10.1016/j.neulet.2021.136362. Epub 2021 Nov 25. PMID: 34838926.
Copy Download .nbib Format: NLM
Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas.

Clinical neuropathology

Dono A, Zhu P, Zorofchian S, Takayasu T, Quezado MM, Rios A, Powers A, Esquenazi Y, Ballester LY.
PMID: 33300867
Clin Neuropathol. 2021 Mar-Apr;40(2):98-107. doi: 10.5414/NP301287.

AIM: Glioblastomas (GBMs) and diffuse intrinsic pontine gliomas (DIPGs) are infiltrating gliomas with poor prognosis. CXCR4 has been linked to glioma cell invasion, survival, proliferation, and angiogenesis. This study aimed to evaluate the expression of CXCR4 in molecular subtypes...

Cite
Dono A, Zhu P, Zorofchian S, et al. Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. Clin Neuropathol. 2021;40(2):98-107doi: 10.5414/NP301287.
Dono, A., Zhu, P., Zorofchian, S., Takayasu, T., Quezado, M. M., Rios, A., Powers, A., Esquenazi, Y., & Ballester, L. Y. (2021). Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. Clinical neuropathology, 40(2), 98-107. https://doi.org/10.5414/NP301287
Dono, Antonio, et al. "Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas." Clinical neuropathology vol. 40,2 (2021): 98-107. doi: https://doi.org/10.5414/NP301287
Dono A, Zhu P, Zorofchian S, Takayasu T, Quezado MM, Rios A, Powers A, Esquenazi Y, Ballester LY. Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas. Clin Neuropathol. 2021 Mar-Apr;40(2):98-107. doi: 10.5414/NP301287. PMID: 33300867.
Copy Download .nbib Format: NLM
Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach.

Annals of surgical treatment and research

Tominaga T, Nonaka T, Fukuda A, Shiraisi T, Hashimoto S, Araki M, Sumida Y, Sawai T, Nagayasu T.
PMID: 34386459
Ann Surg Treat Res. 2021 Aug;101(2):102-110. doi: 10.4174/astr.2021.101.2.102. Epub 2021 Jul 29.

PURPOSE: Pelvic exenteration (PE) is a highly invasive procedure with high morbidity and mortality rates. Promising options to reduce this invasiveness have included laparoscopic and transperineal approaches. The aim of this study was to identify the safety of combined...

Cite
Tominaga T, Nonaka T, Fukuda A, et al. Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach. Ann Surg Treat Res. 2021;101(2):102-110doi: 10.4174/astr.2021.101.2.102.
Tominaga, T., Nonaka, T., Fukuda, A., Shiraisi, T., Hashimoto, S., Araki, M., Sumida, Y., Sawai, T., & Nagayasu, T. (2021). Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach. Annals of surgical treatment and research, 101(2), 102-110. https://doi.org/10.4174/astr.2021.101.2.102
Tominaga, Tetsuro, et al. "Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach." Annals of surgical treatment and research vol. 101,2 (2021): 102-110. doi: https://doi.org/10.4174/astr.2021.101.2.102
Tominaga T, Nonaka T, Fukuda A, Shiraisi T, Hashimoto S, Araki M, Sumida Y, Sawai T, Nagayasu T. Combined transabdominal and transperineal endoscopic pelvic exenteration for colorectal cancer: feasibility and safety of a two-team approach. Ann Surg Treat Res. 2021 Aug;101(2):102-110. doi: 10.4174/astr.2021.101.2.102. Epub 2021 Jul 29. PMID: 34386459; PMCID: PMC8331559.
Copy Download .nbib Format: NLM
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.

Nature

Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K.
PMID: 34823256
Nature. 2021 Nov 25; doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25.

During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, at the time of writing, four variants of concern are considered to...

Cite
Saito A, Irie T, Suzuki R, et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2021;doi: 10.1038/s41586-021-04266-9.
Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J., Iwatsuki-Horimoto, K., Ito, M., Yamayoshi, S., Loeber, S., Tsuda, M., Wang, L., Ozono, S., Butlertanaka, E. P., Tanaka, Y. L., Shimizu, R., Shimizu, K., Yoshimatsu, K., Kawabata, R., Sakaguchi, T., Tokunaga, K., Yoshida, I., Asakura, H., Nagashima, M., Kazuma, Y., Nomura, R., Horisawa, Y., Yoshimura, K., Takaori-Kondo, A., Imai, M., Tanaka, S., Nakagawa, S., Ikeda, T., Fukuhara, T., Kawaoka, Y., & Sato, K. (2021). Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature, . https://doi.org/10.1038/s41586-021-04266-9
Saito, Akatsuki, et al. "Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation." Nature vol. (2021). doi: https://doi.org/10.1038/s41586-021-04266-9
Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2021 Nov 25; doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25. PMID: 34823256.
Copy Download .nbib Format: NLM
Showing 145 to 151 of 151 entries